IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 69.86

Change

-0.44 (-0.63)%

Market Cap

N/A

Volume

0.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-03 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-1.38 (-0.90%)

USD 41.71B
FHLC Fidelity® MSCI Health Care In..

-0.71 (-0.98%)

USD 2.97B
FXH First Trust Health Care AlphaD..

-1.54 (-1.40%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

-1.47 (-1.67%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.35 (-1.43%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

-0.57 (-1.53%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

-1.47 (-1.55%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.56 (-1.91%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.89 (-1.41%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.36 (-1.32%)

USD 0.01B

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.04% 100% F 66% D+
Dividend Return 1.50% 100% F 30% F
Total Return 14.54% 100% F 63% D
Trailing 12 Months  
Capital Gain 19.49% 62% D 52% F
Dividend Return 1.82% 100% F 26% F
Total Return 21.31% 67% D+ 48% F
Trailing 5 Years  
Capital Gain 48.81% 57% F 69% C-
Dividend Return 8.59% 94% A 28% F
Total Return 57.40% 62% D 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 6.38% N/A N/A 59% D-
Dividend Return 7.74% N/A N/A 56% F
Total Return 1.36% N/A N/A 32% F
Risk Return Profile  
Volatility (Standard Deviation) 11.19% N/A N/A 75% C
Risk Adjusted Return 69.20% N/A N/A 83% B
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike